Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.64 |
| ▸ | RARG | P13631 | 13/20 | 0.64 |
| ▸ | RARA | P10276 | 13/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437231 | 0.86 | RARB (0.66) | RARBRARGRARAPLAURXRA | |
| SCHEMBL8709650 | 0.85 | CYP11B2 (0.58) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8709424 | 0.83 | RARB (0.63) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6548975 | 0.83 | RARA (0.43) | RARBRARGRARAPGRPLAU | |
| SCHEMBL8438952 | 0.82 | RARB (0.56) | RARBRARGRARAPLAURXRA | |
| SCHEMBL8706490 | 0.79 | RARB (0.85) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8706311 | 0.79 | RARB (1.00) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8709506 | 0.77 | RARB (0.80) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8705923 | 0.77 | RARA (0.51) | RARBRARGRARAPGRPLAU | |
| SCHEMBL8705921 | 0.76 | RARA (0.48) | RARBRARGRARAPLAUEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122080-A1 | Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122080-A1 | Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | RARA, RARG, RARB | RARB 3/4885RARG 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.